EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces ...
First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC ...
The market presents significant opportunities driven by high demand for biologics and protein therapeutics, as well as ...
The global biopharmaceutical market is driven by the rising prevalence of chronic diseases and biotechnology advancements, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results